Inhibition of Cellular Tryptase Activity assessed through assay of Lysates or Degranulation. HMC1 cells were plated on gelatin-coated 96 well plates in IMDM containing 2% NCS. Cells were treated with inhibitors (10nM-100µM) in 100µL for 2h and subsequently washed in PBS. Degranulation was induced with 1 µM of the calcium ionophore, A23187 in PBS. After 1h the supernatant was assayed for tryptase activity as described above. Alternatively, inhibitor-treated cells were lysed in buffer (50mM HEPES, 150mM NaCl, pH 7.4, 0.1% TX-100, with 1mM EDTA, 20μg/ml heparin, 0.5mg/ml soybean trypsin inhibitor, 100nM aprotinin, 0.5 μg /ml pepstatin, and 100 µM N-Ethylmaleimide) and assayed for tryptase activity.
Tryptase Reversibility studies. Bound inhibitors (10 µM) to tryptase (100nM) were separated from unbound using 7 kD cut-off Zeba desalting columns (Pierce), which had been equilibrated with 1M NaCl immediately prior to use. The subsequent eluant was diluted 1:100 in assay buffer and monitored over 216h for tryptase activity as described above.
Tryptase activity in controls was consistent with ≥ 90% recovery of the enzyme.
Crystallography. The protein complexes with inhibitors were formed by the addition of 1mM compound to recombinant human β-Tryptase (1.95mg/ml, Promega). The protein-compound mixtures were incubated on ice for 30 minutes and spun down to remove the precipitate. The co-crystallizations were setup using the vapor diffusion method, in brief equal volumes of the protein complex and a reservoir solution (30% PEG 1500, 100mM sodium acetate pH 4.6 and 200mM ammonium sulfate) were mixed and subsequently incubated at 25°C. Monocrystals grew to usable size in 3-5 days. Once formed, a monocrystal was soaked for 20 hours in a solution containing 30% PEG 1500, 200mM ammonium sulfate, 100mM MES pH 5.5 and 1mM compound and flash-frozen in liquid nitrogen until the x-ray diffraction.
Synthesis of compounds:
General procedures. Preparative purification of the compounds were performed on Shimadzu preparative HPLC system composed of the following: CBM-20A system controller, LC-8A binary gradient pump, SPD-M20A photodiode array detector, FRC-10A fraction collector, YMC ODS A 500 X 30mm X 10μm preparative column using 0.05% (v/v) trifluoroacetic acid (TFA) in HPLC grade water (A) and 0.05% (v/v) TFA in HPLC grade acetonitrile (B) at a flow rate of 30mL/min and a run time of 40min. For basic medium purification, the same instrument was utilized with YMC triart C18, 500 X 30mm X 10μm preparative column using 10mM ammonium formate and 0.1% (v/v) ammonia in HPLC grade water (A) and HPLC grade acetonitrile adding 5% (v/v) of mobile phase (A) and 0.1% (v/v) ammonia (B). For both the methods, linear gradient profiles were used depending upon the chromatographic retention and separation of different compounds.
LCMS data was collected on Shimadzu LCMS system equipped with CBM-20A system controller, LC-20AD binary gradient pump, SPD-M20A photodiode array detector, SIL-20AC autosampler, CTO-20AC column oven, LCMS-2010EV single -3 -quadrapole mass spectrometer, YMC ODS A 50 X 4.6mm X 3.0μm column using 0.05% (v/v) TFA in HPLC grade water (A) and 0.05% (v/v) TFA in HPLC grade acetonitrile (B) at a flow rate of 1.2mL/min and a run time of 5.0min. The gradient profiles are 20% B to 100% B in 3 minutes, Hold for 0.5min, at 3.51min 20% B, Hold until 5.0min. Maxplot Conditions:
wavelength range is 210-400nm. 
A) Ammonium

tert-Butyl N-[[3-[1-[3-[2-hydroxy-2-(1-hydroxycyclobutyl)ethoxy]benzoyl]-4-piperidyl]phenyl]methyl]-carbamate (32):
A solution of 31 (0.23g, 0.47mmol) in acetone (7mL) and H2O (1.5mL) was charged with 4% solution of OsO4 (0.012mL, 0.0185mmol) and stirred at RT for 10min then charged with a 50% aqueous solution of NMO (0.13mL, 0.56mmol) and stirred at RT for an additional 15h. The reaction mixture was quenched with 10% aqueous sodium bisulphite and stirred for 1h at RT, then the aqueous layer was extracted with EtOAc (3 x 20mL). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The crude product was purified by chromatography on silica gel (60-120 mesh) [eluting with 50% EtOAc in n-hexane] to resulting in 0.18g, 73% yield of 32 as a colorless oil. 1 -6 -
Benzyl 3-(1-(3-aminobenzoyl) piperidin-4-yl) benzylcarbamate (37):
A solution of compound 36 (1.6g, 2.94mmol) in 16mL of methanol and 6.4mL of conc. HCl was allowed to stir at RT for 16h. The solvent was removed under reduced pressure and water (20mL) was added to the reaction mixture followed by basified to pH 9-10 with 2 N NaOH solution. The aqueous layer was extracted with EtOAc (3 x 30mL). The combined organic fractions were washed with water (20mL), brine (10mL) and dried over anhydrous Na2SO4. The organic layer was filtered, concentrated and evaporated under reduced pressure to isolate crude compound. The compound was purified by column chromatography on silica gel (60-120 mesh)
eluting with 0→80% EtOAc in n-hexane giving 1.10g of 37 in 84% yield as white solid. 1 NMR (400MHz, DMSO-d6): δ=1.86 (s, 3H), 2.15 (s, 3H), 5.86 (s, 1H), 7.40 (t, J=7.6Hz, 1H), 7.59 (d,   J=7.6Hz, 1H), 7.82 (d, J=7.6Hz, 1H), 8.27 (s, 1H), 10.0 (s, 1H), 12.8 (br, 1H) N-[[3-[1-[3-[(2,3-dihydroxy-3-methyl-butanoyl) A solution of 46 (0.027g, 0.055mmol) in acetone (2mL) and H2O (0.3mL) was charged with OsO4 (4% aqueous solution, 0.013mL, 0.0022mmol ) and stirred for 10min at RT followed by addition of NMO (50% aqueous solution, 0.015mL, 0.066mmol) and stirred at RT overnight. The reaction mixture was quenched with 10% aqueous sodium bisulphite and stirred for 1h at RT. The aqueous layer was extracted with EtOAc (3x15mL) and the combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated in vacuo resulting in crude compound. The crude product was purified by chromatography silica gel (100-200 mesh) [eluting with 60→80% EtOAc in n-hexane] resulting in 0.017g (60% yield) of compound 47 as an off-white solid. 1 Resolution information and other structural parameters for the crystal structures are given in Table S3 . (b) Dose response curves demonstrate significant leftward shift of the homodimerizing compounds relative to the nondimerizable controls. IC50s and fold-improvements are given in figure 2 . (c) The high stability of tryptase's proteolytic activity at room temperature enabled reversibility studies of compounds to be conducted over an extended period of time. After the removal of excess unbound inhibitor from tryptase by a gel filtration spin-column we monitored the recovery of enzymic activity. Monomeric inhibitors were readily dissociated under these conditions to immediately restore full tryptase activity, while less than 25% of activity was recovered after 7 days with homodimeric compounds.
-11 - Table S1 X-ray data collection and refinement statistics. † The highest resolution shells are shown in parentheses. ‡ Rsym = Σ |Ii -<I>| /
